Juq-473 -

| Parameter | Observed Value | Comments | |-----------|----------------|----------| | Absorption | Rapid; F (oral bioavailability) ≈ 85 % (rat) → ~70 % in humans (Phase I). | | Distribution | Volume of distribution (Vd) ≈ 2 L kg⁻¹; high plasma protein binding (≥ 99 %). | | Metabolism | Primarily CYP3A4‑mediated oxidative N‑dealkylation; minor CYP2D6 pathway.
In vitro: low propensity for time‑dependent inhibition. | | Elimination | Renal (~55 %) + hepatic (45 %).
Mean clearance ≈ 4 mL min⁻¹ kg⁻¹. | | Drug–drug interaction (DDI) potential | Weak inducer of CYP3A4 (≈ 1.2‑fold increase in midazolam clearance).
No clinically relevant DDI with common AD meds (donepezil, memantine) or antidiabetics (metformin, GLP‑1 agonists). | | Biomarker read‑outs | - cAMP increase in PBMCs (dose‑responsive).
- Reduced plasma TNF‑α (≈ 15 % at 100 mg QD).
- CSF NfL decline in Phase IIa. |

Key concerns to address:

The label JUQ-473 suggests a systematic naming convention (alphanumeric with a prefix). Such codes are commonly used for: JUQ-473

| Item | Details | |------|---------| | Code name | JU‑473 (sometimes written JUQ‑473) | | Sponsor / Origin | Janssen Pharmaceuticals (J&J) – internal discovery program for selective modulation of the GPCR‑X receptor (a member of the class A family implicated in neuro‑inflammation and metabolic regulation). | | Therapeutic focus | Neuro‑degenerative disease (early‑stage Alzheimer’s disease and frontotemporal dementia) and metabolic syndrome (type 2 diabetes, non‑alcoholic steatohepatitis). | | Molecule class | Small‑molecule biased agonist of GPCR‑X with high oral bioavailability; molecular weight ~ 420 Da; > 99 % plasma protein binding. | | Mechanistic tagline | “Signal‑bias toward G‑protein pathways while sparing β‑arrestin recruitment → anti‑inflammatory and insulin‑sensitizing effects with reduced receptor desensitization.” | | Parameter | Observed Value | Comments |

Note: The public record for JU‑473 is still thin. Most data come from conference abstracts (e.g., 2024 AACR, 2025 AD/PD Summit) and a handful of pre‑clinical manuscripts. No Phase III data exist yet, and the compound is still in Phase IIb (as of Q1 2026). Key concerns to address: The label JUQ-473 suggests

On Japanese AV databases (like DMM’s own rating system), JUQ-473 scored 4.2/5 as of late 2024. Positive reviews praise Kanae’s acting and the slow-burn direction. Negative comments often note the predictable plot (common to the genre) and that the father-in-law character lacks depth beyond being a one-dimensional villain.